Individuals with cystic fibrosis and pancreatic insufficiency have a gradual decline in insulin secretion over time, which results in an increase in the prevalence of diabetes with age; up to 50% of adults with cystic fibrosis aged over 35 years have diabetes. Cystic fibrosis-related diabetes differs from Type 1 and Type 2 diabetes in several ways; there is a pattern of insulin deficiency with reduced and delayed insulin response to carbohydrates but a sparing of basal insulin that results in glucose abnormalities, which are frequently characterized by normal fasting glucose and postprandial hyperglycaemia. Insulin deficiency and hyperglycaemia, even at levels which do not reach the threshold for a diagnosis of diabetes, have an adverse impact on lung function and clinical status in people with cystic fibrosis. Although the risk of microvascular complications occurs as in other forms of diabetes, the main reason for treatment is to prevent deterioration in lung function and weight loss; treatment may therefore be required at an earlier stage than for other types of diabetes. Treatment is usually with insulin, but management needs to take into account all the other medical issues that arise in cystic fibrosis.
Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder caused by a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Progress in treatment for CF has increased life expectancy; in the 1960s, survival beyond childhood was rare, but now the median life expectancy is >45 years. CF has multisystem effects, and clinical features include pulmonary infections with deteriorating lung function, exocrine pancreatic failure, liver disease and osteoporosis. CF-related diabetes (CFRD) is a common complication of CF, with an increasing prevalence with age; up to 50% of adults with CF develop CFRD by the age of 35 years [1] . Increased life expectancy in CF has resulted in a steady increase in the number of adults with CF and the prevalence of CFRD. Of the 10 810 people recorded in the CF Trust registry for 2015, 1982 (18.3%) were receiving diabetes treatment [2] .
The pathophysiology of CFRD differs from that of Type 1 and Type 2 diabetes (Table 1 ). In CRFD, there is a reduced and delayed insulin response to carbohydrates while basal insulin is often spared. This leads to glucose abnormalities, which are frequently characterized by normal fasting glucose and postprandial hyperglycaemia. CFRD and hyperglycaemia, at levels below the diagnostic threshold for diabetes, have an adverse impact on clinical status and lung function in CF. These differences require a unique clinical approach to CFRD with regard to screening, diagnosis and management.
In the present review, we will describe the glucose and insulin abnormalities in CF and the adverse impact of CFRD on clinical status before discussing the approach to diagnosis and treatment compared with Type 1 and Type 2 diabetes.
Methods
The present review is based on a symposium held on 9 March 2017 at the Diabetes UK Professional Conference. The authors undertook a literature review in preparation for the meeting and synthesized their findings into this review.
Pathophysiology of cystic fibrosis-related diabetes
Cystic fibrosis-related diabetes occurs almost exclusively in individuals with pancreatic insufficiency, which occurs in most people with CF. There is a progressive decrease in insulin secretion with increasing age, and a decrease in the number of pancreatic insulin-secreting b cells. Limited data from postmortem studies suggest a reduction in b-cell numbers, with fibrosis and amyloidosis of the pancreas [3, 4] . Studies of the ferret model of CF show loss of b cells at birth, with further b-cell loss associated with inflammation Correspondence to: Nicola Bridges. E-mail: n.bridges@imperial.ac.uk.
ª 2018 Diabetes UK and fibrosis of exocrine pancreatic tissue [5] . There may also be a direct effect of the CF mutation on insulin secretion, as the CFTR has a role in b-cell function and insulin secretion [6] . As discussed below, ivacaftor, a drug that reverses the effect of CFTR mutations in some genetic forms of CF, improves insulin secretion and diabetes control [7] .
Insulin and glucose abnormalities in cystic fibrosis-related diabetes
The main defect in CFRD is insulin deficiency. Insulin secretion in people with CF declines from childhood [1, 8] , even in individuals with normal glucose levels [9, 10] . Insulin sensitivity is usually normal in CF [11] , but reduced insulin sensitivity contributes to hyperglycaemia in situations where there is another cause of insulin resistance, such as infection or systemic corticosteroid treatment. Basal insulin secretion is relatively preserved, but the insulin response to a glucose load is reduced and delayed. Consequently, fasting glucose levels are often normal at the start of CFRD and can remain so for years. There is a characteristic pattern of abnormal glucose levels; glucose is lowest before breakfast and rises after meals, with the highest levels after the evening meal (Fig. 1) .
The delay in insulin secretion commonly results in hypoglycaemia, even in individuals who do not have CFRD. Among children and adolescents with CF, 13% experience hypoglycaemia during routine oral glucose tolerance tests (OGTTs), and this represents a mismatch between the prompt absorption of an oral glucose solution and delayed first-phase insulin secretion in CF [12] . Those with hypoglycaemia during the OGTT do not appear to have an increased risk of developing diabetes [1] . Reactive hypoglycaemia may also occur, typically 1-2 h after a meal or drink that is high in refined carbohydrate and low in fat, most likely after breakfast. Individuals with hypoglycaemia after meals can be symptomatic and need advice on the avoidance of hypoglycaemia through dietary modification. Ketosis and diabetic ketoacidosis are unusual in CFRD.
Impact of diabetes on cystic fibrosis
The impact of CFRD on mortality has been recognized for a long time, with registry studies from the 1980s and 1990s showing significant increases in mortality in CFRD [13, 14] , even after adjustment for other risk factors. In 2005, Milla et al. [15] published retrospective data showing that, compared to those with no diabetes, CFRD resulted in a 17-year What's new?
• Cystic fibrosis-related diabetes (CFRD) is distinct from Type 1 and Type 2 diabetes.
• CFRD and impaired glucose tolerance have an adverse effect on clinical status in cystic fibrosis (CF), and treatment of CFRD is primarily aimed at reducing this impact.
• Treatment may be required at an earlier stage than for other types of diabetes to prevent deterioration of lung function and weight loss.
• The treatment of choice is insulin but should take account of other medical issues in CF.
decrease in median survival rates in women, with no significant difference in men (although other studies have shown an impact in men as well [16] ). The same group published data for more recent cohorts in the same clinic, showing reductions in mortality with time. These improvements are likely to be related to earlier recognition of CFRD, screening and treatment. Comparing cohorts for 1992-1997 and 2008-2012, age-adjusted mortality for individuals with CFRD fell from 4.9 to 1.8 per 100 person-years [17] . Differences for adults with CFRD, however, still persist; overall mortality in the latest cohort was doubled compared with that in adults with CF without diabetes. Genotype affected both mortality and diabetes risk: adults with severe CFTR genotypes experienced greater mortality at every age >32 years than adults with milder genotypes, and the risk of CFRD was also increased in those with severe genotypes [17] .
There is evidence of deteriorating health status for 2-6 years prior to a diagnosis of CFRD. Finkelstein et al. [18] reported clinical deterioration in National Institute of Health scores (which look at clinical markers of disease severity in CF) in 448 people with CF up to 2 years prior to the diagnosis of CFRD. Furthermore Lanng et al. [19] reported decreases in weight, BMI and markers of lung function up to 6 years prior to the diagnosis of CFRD. Women may experience this decline more quickly than men. Trials assessing the impact of insulin therapy have also reported clinical decline prior to insulin initiation [20] .
The reasons why worsening glycaemia adversely affects clinical status are not fully understood but are likely to be multifactorial. There is a gradual loss of the anabolic effect of insulin, leading to weight and lean body mass loss, which is an independent predictor of survival. Increasing airway glucose levels may be an additional factor, promoting bacterial growth. Although elevated airway glucose concentrations are seen in people with diabetes without CF, airway glucose levels appear to be higher in people with CFRD [21] . In people with CFRD undergoing continuous glucose monitoring (CGM), glucose was detected in airway secretions when blood glucose levels rose above 8 mmol/l. This level was exceeded for 45% of the day in those with CFRD, compared with 6% of the day in people with CF and normal glucose tolerance. The same study showed that Staphylococcus aureus growth increased when airway glucose levels reached 0.5 mmol/l, while Pseudomonas aeruginosa growth rates increased at 1-4 mmol/l, levels demonstrated in the lungs of people with CFRD. Unsurprisingly, infection rates are increased and lung function declines more quickly in people with CFRD.
There is emerging evidence that hyperglycaemia affects lung function in people with diabetes unrelated to CF; there is loss of lung elasticity and recoil with the stiffened lungs, reflected by reductions in forced expiratory volume in 1 s and forced vital capacity. Diffusion capacity is reduced through thickening in the alveolar epithelium, rather like the changes seen in the diabetic kidney. For the most part in people with diabetes, these changes do not cause a clinical problem but, in the setting of CFRD, the additional burden reduces life expectancy and increases the need for lung transplantation [13] .
Effect of subtle glucose changes on clinical status
The magnitude of hyperglycaemia in CF appears to be linked to clinical status. A UK registry study reported that, among people treated for CFRD over a 2-year period, the mean HbA 1c concentration was 56 mmol/mol (7.3%) in those who died compared with 49 mmol/mol (6.6%) in the survivors, with a threefold increased mortality in those with HbA 1c concentration >48 mmol/mol (6.5%) [22] . The effect of glucose abnormalities on clinical status extends to prediabetes and situations where the diagnostic criteria for diabetes are not met. Clinical status is worse in those with impaired Overnight and fasting glucose levels are normal with raised glucose levels after each meal.
ª 2018 Diabetes UK glucose tolerance after an OGTT, compared with those with normal glucose tolerance [23, 24] . There are a few studies in CF demonstrating an association between clinical status and markers of lung function and relatively minor changes in glucose levels in those who do not meet the criteria for diabetes [25, 26] . CGM frequently demonstrates glucose abnormalities in individuals with CF who have normal glucose tolerance according to the OGTT and HbA 1c concentrations in the non-diabetic range [27] . Leclercq et al. [28] showed that in people with a normal OGTT result, abnormalities on CGM predicted worse lung function [28] . Hameed et al. [29] examined OGTT (with 30-min sampling) and CGM glucose results in a group of 33 children and adolescents. After excluding two individuals who had diabetes on OGTT, they found that a blood glucose level >7.8 mmol/l, measured using CGM, for >4.5% of the time, or a glucose level >8.2 mmol/l at any time during OGTT, correlated with declining weight SD score and lung function in the previous 12 months. The evidence that glucose abnormalities, which do not fulfil the diagnostic criteria for diabetes, can significantly impact clinical status influences the decision to treat CFRD.
Reasons to treat and when to treat
The rationale for treating hyperglycaemia in other type of diabetes is the alleviation of osmotic symptoms and the prevention of the long-term complications. The risk of microvascular and macrovascular complications is related to glycaemia, as measured by HbA 1c , and the need to lower HbA 1c is balanced with the need to avoid iatrogenic side effects, such as hypoglycaemia. While it was previously thought that people with CFRD did not develop microvascular complications, a recent study has suggested that the prevalence of retinopathy is 15% in people whose duration of diabetes is >10 years, with 50% prevelance of neuropathy and 16% of nephropathy [30] . That study found no cases of macrovascular disease. Although treatment of CFRD should prevent microvascular complications, the main challenges in the management of CF are the prevention of lung infection and decline of lung function and weight loss.
A major uncertainty for clinicians looking after people with CFRD is the glucose threshold at which to initiate treatment. It is clear that lung function declines more rapidly in people with CFRD than those with normoglycaemia, leading to increased mortality and lung transplantation rates [13] , but this is also the case for those with CF and impaired glucose tolerance. Thus hyperglycaemia affects the lungs of people with CF at levels well below the current diagnostic criteria for Type 1 and Type 2 diabetes (based on OGTT, fasting glucose or HbA 1c ). Although the American Diabetes Association guidelines endorse the standard diagnostic criteria for CFRD, lower thresholds for people with CF may be more appropriate, not least because there is evidence of benefit from treatment in individuals who do not reach the standard diagnostic criteria for diabetes. At present, however, there is no international consensus on this.
Our view is that that individuals who meet the diagnostic criteria for diabetes should be treated; however, treatment should be also considered for individuals with abnormal glucose levels which do not meet the criteria for diabetes (for example, impaired glucose tolerance on OGTT or postprandial glucose levels >8 mmol/l), if there is evidence of declining lung function or weight loss.
Screening for cystic fibrosis-related diabetes
The clinical impact of CFRD has resulted in an increased awareness of the importance of monitoring glucose levels and prompted the introduction of systematic screening as part of the routine annual CF review. OGTT remains the commonest screening test and yearly OGTT is suggested in CF Trust and American Diabetes Association guidelines, commencing from 10 years of age [31, 32] . The pattern of glucose abnormalities in CFRD means that fasting glucose is usually unhelpful.
Although the OGTT is widely used as a screening tool in CF, it may not be the best way of assessing glucose status. The insulin abnormalities in CF mean that glucose levels can be high during an OGTT but 'normal' at 120 min [9, 24] . Some centres measure glucose at 30-min intervals during the test to obtain more information, and a classification of glucose status based on this has been suggested [33] . There has been interest in assessing glucose status using CGM and, more recently, in intermittently scanned CGM (flash glucose monitoring). Caution is needed when undertaking screening during acute illness because temporary hyperglycaemia may occur at this time.
Concentration of HbA 1c is measured at annual review in people with CF and is used to monitor treatment of CFRD. There is no evidence for the use of HbA 1c to diagnose CFRD, although one study examined the use of HbA 1c as a screening test before an OGTT [34] . HbA 1c is affected by the lifespan of red blood cells; under normal circumstances it provides a retrospective measure of the average glucose concentration over the previous 6-8 weeks. In CFRD, however, there are a number of conditions that affect red blood cell turnover. Iron deficiency occurs commonly in CF and may be associated with higher HbA 1c in people with diabetes. Conversely, increased red cell turnover, which is associated with reduced HbA 1c , has also been observed in CF.
How should we treat cystic fibrosis-related diabetes?
Dietary advice in cystic fibrosis
Cystic fibrosis creates a catabolic state through increased energy expenditure, partly as a result of increased work of breathing and frequent infection. CF is also associated with malabsorption, exocrine pancreatic enzyme deficiency and abnormal intestinal transit times. The goal of nutritional management in CF is to provide a high-calorie diet through increased macronutrient provision. Often, supplements or enteral tube feeding are needed. Routine supplementation with multivitamins and additional fat-soluble vitamins A, D, E and K are needed, together with liberal sodium intake.
Many adults with CF have unusual eating patterns. Diet and calorie intake have been a focus for them since childhood, concentrating on snacks, sweet and high-calorie foods, and they often omit breakfast because they have their physiotherapy in the morning and do not feel like eating.
The need to consume an above-normal calorie intake to maintain weight must continue when diabetes is diagnosed and dietary restrictions should not be imposed. If necessary, insulin treatment should be tailored to cover the food intake (including supplements and feeds). Standard dietary advice for people with Type 2 diabetes which promotes weight loss and high fibre intake is not suitable in those with CF. In CFRD management it is reasonable to advise avoidance of heavily refined sugars, such as sugary carbonated beverages but, largely, the CF dietary needs outweigh those of diabetes. Physical activity should be encouraged because this is beneficial for both lung function and glycaemic control.
Many people with CF take pancreatic enzyme supplementation to improve food absorption and prevent steatorrhoea. This is also important for optimal glucose control. People with CF have rapid gastric emptying and impaired incretin hormone secretion, which can be improved at least in part by pancreatic enzyme supplementation [35] .
Insulin and other antidiabetes drugs
The mainstay of treatment in CFRD is insulin, although some studies have reported the use of sulfonylureas, and there are ongoing trials of dipeptidyl peptidase-4 inhibitors. Sulfonylureas have a limited duration of response, with most people ultimately needing insulin, most likely as a result of ongoing b-cell damage. Treatment with insulin has been associated with up to 22-mmol/mol (2%) improvement in HbA 1c after 1 year's treatment, and 11-mmol/mol (1%) improvement after 5 years, although other studies have shown less benefit. Improved glycaemic control is associated with improvements in body weight (BMI improvement of 1-3 kg/m 2 ) and lung function (6-35% increased forced expiratory volume in 1 s) [36] . Insulin therapy may also lead to a reduction in the frequency of chest infections [37] , although this has not been demonstrated in all studies. There is no convincing evidence to support the use of one regimen or type of insulin over another as different insulin regimens have demonstrated improved nutritional markers and lung function with insulin treatment [36, 38, 39] . The insulin regimen should be individualized to the patient's needs; for example, for someone with postprandial hyperglycaemia, mealtime rapid-acting insulin may suffice, while someone receiving steroids may require an intermediate insulin dose. The management of hyperglycaemia around overnight feeds can be challenging, often requiring a combination of short-and long-acting insulin.
Hypoglycaemia related to treatment with insulin or oral hypoglycaemic agents can occur in CFRD as in anyone receiving these therapies. While people with CF do not have a good glucagon response to hypoglycaemia, the catecholamine response is usually retained. Education on prevention and treatment of hypoglycaemia is important. The effect of hypoglycaemia on driving and the importance of monitoring glucose before driving should be explained. Severe hypoglycaemia, however, appears to be less common in CFRD than in Type 1 diabetes because of the residual endogenous insulin secretion. The risk factors for severe hypoglycaemia (hypoglycaemia requiring the assistance of a third party) and hypoglycaemia unawareness are the same as in Type 1 diabetes.
Effect of medications and illness
The pharmacokinetics of many medications are altered in CF and this can affect glycaemic control in those with CFRD. Prednisolone clearance is increased by 60%, with a 46% increase in volume of distribution and a 35% lower peak concentration [40] . Absorption of medications is also affected; for example, enteric coated prednisolone is very poorly absorbed in CF, and the tablet form of itraconazole is also poorly absorbed unless taken with an acidic substance. If medications are absorbed poorly, this can have a significant effect on glycaemia, altering the impact of prednisolone on glucose levels during the day. On withdrawal of these medications, insulin resistance related to prednisolone disappears rapidly but effects from itraconazole may last months after withdrawal, because of its very prolonged elution from tissues.
Marked alterations in glucose tolerance can occur at the time of infection, even in those without a previous diagnosis of CFRD, because of the impact of the infection and nutrition. On the one hand, calorie requirement may be increased because of infection and increased work of breathing, while on the other hand, calorie intake may be limited through poor appetite because of nausea, vomiting related to swallowed sputum and uncontrolled coughing, particularly in the morning. Many people with CF rely on nutritional supplements to maintain their body weight, with high-calorie high glycaemic index foods causing further glucose excursions.
Effect of CFTR modulators on cystic fibrosisrelated diabetes
The CFTR modulators, such as ivacaftor, are relatively new agents in managing CF, which partially reverse the effects of ª 2018 Diabetes UK the mildest mutations in CF (gating mutations); there are newer agents in development with effects on the more severe mutations. There are case reports of the resolution of CFRD with treatment with ivacaftor [41] . A study in five people with CF (three with normal glucose tolerance, one with recent diagnosis of CFRD and one with CFRD for 16 years) showed that after 1 month's treatment with ivacaftor, the insulin response to oral glucose improved by 66-178%, except for an individual with longstanding diabetes who showed no improvement [7] . The mechanism for this improvement is not wholly understood but points to the role of the CFTR in the regulation of insulin secretion.
Monitoring and glycaemic targets in cystic fibrosis-related diabetes
Tight glycaemic control will reduce the adverse impact of CFRD on clinical status [22] as well as reducing the risk of microvascular complications. The burden of all the other therapies for CF must be taken into account when supervising diabetes management in CF; however, improved diabetes control can have a positive impact on clinical status and patient well-being and so intensive treatment can be justified even in individuals with complex problems and poor lung function. Those with frequent infective episodes or receiving intermittent high-dose steroids may need to make frequent dose adjustments.
To support tight glycaemic control, people with CFRD are advised to self-monitor their capillary glucose or undertake CGM if this is available. This needs to be individualized, with those taking insulin needing more testing than those on diet and lifestyle modification alone. Increased testing may be needed at times when insulin requirements change, such as during a period of infection.
Glucose levels should be checked in any individual with CF commenced on enteral tube feeding. The CF Trust recommends glucose testing pre-feed, 2 h into the feed and immediately post-feed to ascertain whether additional insulin is required [31] . The type and dose of insulin prescribed depends on the profile of glucose levels during the feed and on the duration of the feed. It is important to repeat these measurements if changes are made to the feed type, volume or duration, and also if the patient's clinical status changes, for example, during illness or after changes in weight. There is a risk of hypoglycaemia if the feed is interrupted after insulin has been given or if the feed is not completed or regurgitated. Overnight percutaneous endoscopic gastrostomy (PEG) feeding pumps should have an appropriate alarm, which sounds if the feed stops so that hypoglycaemia does not ensue.
Despite the caveats relating to the use of HbA 1c , this should be monitored regularly in people with CFRD. Furthermore, microvascular screening for retinopathy, neuropathy, foot problems and nephropathy should be performed as for the wider population of people with diabetes.
Cystic fibrosis-related diabetes and lung transplantation
In 2015 in the UK, 46 adults with CF received transplants, 42 bilateral lung transplant and the others liver or kidney. As the median survival after lung transplantation is currently 5 years, this procedure is only offered for end-stage lung disease; nevertheless, it increases life expectancy, with~20% surviving >10 years after transplant [42] . The prevalence of diabetes is high before transplantation, and many individuals develop diabetes shortly afterwards. In a study from the Netherlands, 63% of individuals with CF had diabetes before lung transplant and 80% after. CFRD diagnosed before transplant increased mortality [43] .
Long-term steroid treatment taken after transplant has an adverse impact on glycaemic control, and the need to carry on with some aspects of CF treatment (such as enzyme replacement) and anti-rejection drugs, as well as diabetes management, means these individuals may have a very complex drug regimen that can be challenging to maintain. There are no data about the impact of glycaemic control on long-term survival after transplant.
Burden of disease
There have been few studies on the burden of CFRD, but one study reported that CFRD has less effect on quality of life than did Type 1 diabetes [44] . People with CFRD take multiple medications and adherence to diabetes self-management plans can be challenging. To date, there have been no studies examining the effect of insulin therapy on quality of life.
Diabetes services in cystic fibrosis
One of the major challenges in the organization of CF services is the prevention of cross-infection. Dedicated clinic areas without communal waiting areas are needed, with clinicians moving to the patient rather than vice versa. As a result, structured group diabetes education is not feasible and one-to-one training is needed.
Most large CF centres now have dedicated CFRD clinics, which allow CFRD management to be considered alongside the wider management of CF, as well as meeting the standards for reducing cross infection.
Management of diabetes must take into account the practical and psychological effects of adding insulin treatment to the other treatments for CF. For some individuals with CF, diabetes care is shared between their CF centre, primary care and sometimes another diabetes service. This can help with the practical management of diabetes and routine screening, but it is important people are not incorrectly labelled as having Type 1 or Type 2 diabetes, given incorrect dietary advice or put on inappropriate oral agents. Diabetes self-management education, including information about the unique nature of CFRD, can help support people with CFRD in their interactions with health professionals.
Conclusion
Cystic fibrosis-related diabetes is a unique form of diabetes that is becoming more common as individuals with CF live longer. It is characterized by insulin deficiency and periods of reduced insulin sensitivity. Postprandial hyperglycaemia with normal fasting glucose levels are the most frequently seen abnormalities. Diabetes and hyperglycaemia, even at levels that do not reach the threshold for a diagnosis of diabetes, have an adverse effect on lung function and clinical status and this is the primary reason for starting treatment. Individuals who do not meet the criteria for a diagnosis of diabetes may therefore benefit from treatment, although the criteria to start treatment and the best way to screen remain uncertain. Insulin deficiency is present in early childhood and gradually worsens with age, but it is not clear at which point starting treatment leads to clinical benefit.
The mainstay of treatment is insulin but new therapies are being investigated. In particular, the novel CFTR modulators, such as ivacaftor, appear to improve glucose tolerance.
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